Form 8-K · Current Report · Filed 2025-03-10
Illumina Announces Fiscal Year 2025 Guidance and Cost Reductions Amid China Export Ban
Illumina, Inc. announced on March 10, 2025, that it respects the China Ministry of Commerce's decision to prohibit the export of sequencing instruments into China. The company expects its Core Illumina fiscal 2025 non-GAAP diluted EPS to be approximately $4.50 and is implementing a cost reduction program of about $100 million for fiscal 2025 to mitigate the potential impact of reduced revenue from its Greater China business.
- Filer
- Illumina, Inc. ILMN · NASDAQ
- Filed
- Accession
- 0001110803-25-000025
- CIK
- 0001110803
- Signal
- Low impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Regulation FD Disclosure
Financial Statements and Exhibits
Market reaction
Close before filing
$86.62
Next session
-2.4%
Since filing
+136.8%
Latest close
$205.10
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from ILMN reporting the same item, with the next session's move:
Exhibits (1)
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Never miss another ILMN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.